Evidence map›Paper›PMID 36272768›Full record

ArticleSurgery2023

Association of comprehensive thyroid cancer molecular profiling with tumor phenotype and cancer-specific outcomes.

Jason B Liu, Kimberly M Ramonell, Sally E Carty, Kelly L McCoy, Barry M Schaitkin, Esra Karslioglu-French, Elena M Morariu, N Paul Ohori, Raja R Seethala, Simion I Chiosea and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Surgery, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Review
  3. Development of Novel mRNA Classifiers to Stratify Preoperative Thyroid Tumor Risk.Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · 2026
    Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jason B LiuDivision of Endocrine Surgery, Department of Surgery, University of Pittsburgh, PA.
Kimberly M RamonellDivision of Endocrine Surgery, Department of Surgery, University of Pittsburgh, PA.
Sally E CartyDivision of Endocrine Surgery, Department of Surgery, University of Pittsburgh, PA.
Kelly L McCoyDivision of Endocrine Surgery, Department of Surgery, University of Pittsburgh, PA.
Barry M SchaitkinDepartment of Otolaryngology, University of Pittsburgh, PA.
Esra Karslioglu-FrenchDivision of Endocrinology and Metabolism, Department of Medicine, University of Pittsburgh, PA.
Elena M MorariuDivision of Endocrinology and Metabolism, Department of Medicine, University of Pittsburgh, PA.
N Paul OhoriDivision of Molecular and Genomic Pathology, Department of Pathology, University of Pittsburgh, PA.
Raja R SeethalaDivision of Molecular and Genomic Pathology, Department of Pathology, University of Pittsburgh, PA.
Simion I ChioseaDivision of Molecular and Genomic Pathology, Department of Pathology, University of Pittsburgh, PA.
Marina N NikiforovaDivision of Molecular and Genomic Pathology, Department of Pathology, University of Pittsburgh, PA.
Yuri E NikiforovDivision of Molecular and Genomic Pathology, Department of Pathology, University of Pittsburgh, PA.
Linwah YipDivision of Endocrine Surgery, Department of Surgery, University of Pittsburgh, PA. Electronic address: yipl@upmc.edu.

Funding

VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Leonard J. Appleman · 1988 to 2026
$158.0M
NCI NIH HHS P30 CA047904
6 · The paper itself

Abstract

backgroundMolecular testing improves the diagnostic accuracy of thyroid cancer. Whether specific molecular testing results are associated with tumor phenotype or provide prognostic information needs further delineation.

methodsConsecutive thyroid cancer patients after index thyroidectomy with ThyroSeq version 3 (Rye Brook, NY) molecular testing obtained on preoperative fine-needle aspiration or thyroidectomy specimens from patients with thyroid cancer were categorized into 3 molecular risk groups based on detected mutations, fusions, copy number alterations, and/or gene expression alterations and correlated with histopathology and recurrence, defined as biochemical or structural.

resultsOf 578 patients, 49.9%, 37.5%, and 12.6% had molecular risk group-low, molecular risk group-intermediate, and molecular risk group-high cancers, respectively. With a median 19-month follow-up, 9.1% patients recurred. Compared with molecular risk group-low, molecular risk group-intermediate cancers were diagnosed in younger patients and more often had microscopic extrathyroidal extension, involved margins, and nodal disease. Compared with molecular risk group-intermediate, molecular risk group-high cancers were diagnosed in older patients and more often had gross extrathyroidal extension and vascular invasion. In multivariable analysis, recurrence was more likely in molecular risk group-high cancers than in molecular risk group-intermediate (hazard ratio = 4.0; 95% confidence interval, 1.9-8.6; P < .001) and more likely in molecular risk group-intermediate than in molecular risk group-low (hazard ratio = 5.0; 95% confidence interval, 2.0-12.5; P < .001).

conclusionUsing modern comprehensive genotyping, the genetic profile of thyroid cancers can be categorized into 3 novel molecular risk groups that were associated with histopathologic phenotype and recurrence in short-term follow-up.

Indexed as

Thyroid NeoplasmsBiopsy, Fine-NeedleHumansPrognosisProportional Hazards ModelsRetrospective StudiesThyroidectomy

Identifiers

PMID36272768
PMCPMC11189592

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.